Recent studies have unearthed fascinating insights into how psilocybin, a naturally occurring compound in certain mushroom species—often referred to...
Recent studies have shed light on the intriguing potential of hallucinogenic mushrooms, specifically those containing psilocybin, in offering therapeutic...
VANCOUVER, BC, March 20, 2024 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF), a mental health care...
SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
Cybin Inc. announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major...
TORONTO – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (‘Cybin’ or the ‘Company’), a clinical-stage biopharmaceutical company committed...
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company...
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group“) (CSE: PSYG), a clinical-stage life science biotechnology company...